- Trials with a EudraCT protocol (231)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
231 result(s) found for: Total lung capacity.
Displaying page 1 of 12.
| EudraCT Number: 2013-001445-13 | Sponsor Protocol Number: CNVA237ADE02 | Start Date*: 2013-08-30 | |||||||||||
| Sponsor Name:Novartis Pharma GmbH | |||||||||||||
| Full Title: A randomized, double-blind, multicenter, 2-period single-dose cross-over study to assess the early bronchodilation of Glycopyrronium bromide (44 µg o.d.) compared to Tiotropium (18 µg. o.d.) in pat... | |||||||||||||
| Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-004684-22 | Sponsor Protocol Number: CQAB149B2318 | Start Date*: 2008-02-18 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: An exploratory, double-blind, randomized, placebocontrolled, 2-way cross-over study to assess the effect of repeat-dose inhaled indacaterol maleate (300 mcg) on dynamic and static lung hyperinflati... | |||||||||||||
| Medical condition: COPD (Chronic Obstructive Pulmonary Disease) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-003551-32 | Sponsor Protocol Number: ISS-U1111-1188-8695 | Start Date*: 2017-11-01 | |||||||||||
| Sponsor Name:Hospital of South West Jutland | |||||||||||||
| Full Title: Effects of GLP-1 receptor agonist treatment on pulmonary function and quality of life in obese patients with chronic obstructive pulmonary disease - A prospective, randomized, placebo-controlled, ... | |||||||||||||
| Medical condition: Chronic obstructive pulmonary disease in obese subjects | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-000485-36 | Sponsor Protocol Number: G0500705 | Start Date*: 2006-08-23 |
| Sponsor Name:Newcastle upon Tyne Hospitals NHS Trust | ||
| Full Title: A randomised, double blind, placebo controlled study to Assess The Effect of Antibiotic Therapy on Chronic Rejection in Human Lung Transplantation | ||
| Medical condition: Post Lung Transplantation Chronic Rejection identified as bronchiolitis obliterans syndrome (BOS) | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2020-002356-20 | Sponsor Protocol Number: CLI-05993BA1-08 | Start Date*: 2021-05-04 | |||||||||||
| Sponsor Name:Chiesi Farmaceutici S.p.A. | |||||||||||||
| Full Title: Open label, prospective study to evaluate the effect of step-up from non-extrafine ICS/LABA DPI to extra fine triple therapy with CHF5993 DPI on airway geometry and lung ventilation using FRI in su... | |||||||||||||
| Medical condition: COPD (Chronic Obstructive Pulmonary Disease) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) HU (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-002744-17 | Sponsor Protocol Number: MA39189 | Start Date*: 2017-03-29 | |||||||||||
| Sponsor Name:Roche Farma S.A, que representa en España a F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: MULTICENTER, INTERNATIONAL, DOUBLEBLIND, TWO-ARM, RANDOMIZED, PLACEBO CONTROLLED PHASE II TRIAL OF PIRFENIDONE IN PATIENTS WITH UNCLASSIFIABLE PROGRESSIVE FIBROSING ILD | |||||||||||||
| Medical condition: Fibrosing interstitial lung disease (ILD) of unknown origin | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) DK (Completed) CZ (Completed) DE (Completed) PL (Completed) PT (Completed) GR (Completed) BE (Completed) GB (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-004680-21 | Sponsor Protocol Number: CQVA149ADE05 | Start Date*: 2015-04-23 | |||||||||||
| Sponsor Name:Novartis Pharma GmbH | |||||||||||||
| Full Title: A randomized, double-blinded, single-center, placebo controlled, cross-over study to assess the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) on cardiac function in patients with... | |||||||||||||
| Medical condition: chronic obstructive pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-003158-18 | Sponsor Protocol Number: 203PF203 | Start Date*: 2018-09-12 | |||||||||||
| Sponsor Name:Biogen Idec Research Limited | |||||||||||||
| Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis | |||||||||||||
| Medical condition: mild to moderate Idiopathic Pulmonary Fibrosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) GB (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) GR (Completed) BE (Completed) ES (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-005602-26 | Sponsor Protocol Number: FL-101-2001 | Start Date*: 2021-08-03 | ||||||||||||||||||||||||||
| Sponsor Name:Flame Biosciences | ||||||||||||||||||||||||||||
| Full Title: A Two-cohort, Phase 2 Study of FL-101 as Neoadjuvant Therapy in Patients with Surgically Resectable Non-Small Cell Lung Cancer | ||||||||||||||||||||||||||||
| Medical condition: Surgically resectable non-small cell lung cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: FR (Prematurely Ended) NL (Prematurely Ended) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2009-009074-27 | Sponsor Protocol Number: ACE-INIBITORE | Start Date*: 2009-03-15 | |||||||||||
| Sponsor Name:PROF. ALFREDO CHETTA | |||||||||||||
| Full Title: Effect of an ACE inhibitor on the exercise capacity of COPD patients. A randomized double-blind placebo-controlled study | |||||||||||||
| Medical condition: PATIENTS AFFECTED BY COPD | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-002094-36 | Sponsor Protocol Number: D3250C00038 | Start Date*: 2016-11-22 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function with Benralizumab in Severe, U... | |||||||||||||
| Medical condition: Asthma | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-019047-19 | Sponsor Protocol Number: 03-2010 | Start Date*: 2010-05-10 |
| Sponsor Name:Pneumologia c/o Villa Pineta | ||
| Full Title: ADDITIONAL EFFECT OF TIOTROPIUM BROMIDE ON EXERCISE TOLERANCE IN COPD PATIENTS. PILOT STUDY | ||
| Medical condition: COPD (Chronic Obstructive Pulmonary Disease) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: IT (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-002324-15 | Sponsor Protocol Number: P01092 | Start Date*: 2007-09-04 | |||||||||||
| Sponsor Name:University of East Anglia | |||||||||||||
| Full Title: The efficacy and safety of co-trimoxazole therapy in patients with idiopathic interstitial pneumonia | |||||||||||||
| Medical condition: Idiopathic Interstitial Pneumonia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-018597-20 | Sponsor Protocol Number: CNVA237A2310 | Start Date*: 2010-08-09 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: A multi-center, randomized, double-blind, placebo- controlled, two-period cross-over study to assess the effect of 50µg inhaled NVA237 on exercise endurance in patients with moderate to severe COPD | |||||||||||||
| Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) DE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-004334-13 | Sponsor Protocol Number: MSI-1995-203 | Start Date*: 2005-04-08 |
| Sponsor Name:Genaera Corporation | ||
| Full Title: A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Talniflumate in Cystic Fibrosis Subjects | ||
| Medical condition: Cystic Fibrosis | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: IE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-004828-66 | Sponsor Protocol Number: MedOPP112 | Start Date*: 2016-07-20 | |||||||||||||||||||||
| Sponsor Name:Medica Scientia Innovation Research (MedSIR ARO) | |||||||||||||||||||||||
| Full Title: A phase IIa clinical trial to evaluate the safety and efficacy of osirmertinib (AZD9291) in first-line patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer... | |||||||||||||||||||||||
| Medical condition: Patients diagnosed with stage IIIB or IV non-small cell lung cancer carrying the EGFR activating mutation and confirming concomitant T790M mutation during screening who have not received prior trea... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Prematurely Ended) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2006-002174-22 | Sponsor Protocol Number: Avifibro | Start Date*: 2006-11-08 |
| Sponsor Name:Mondobiotech Laboratories Anstalt | ||
| Full Title: Influence of inhaled Aviptadil on CCL18 serum concentrations in patients with pulmonary fibrosis | ||
| Medical condition: Pulmonary Fibrosis categorized as UIP or NSIP | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-001163-24 | Sponsor Protocol Number: GB28547 | Start Date*: 2013-11-04 |
| Sponsor Name:F. Hoffmann-La Roche Ltd | ||
| Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS. | ||
| Medical condition: IDIOPATHIC PULMONARY FIBROSIS | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) IT (Completed) ES (Completed) PL (Completed) GB (Completed) BE (Completed) FR (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2008-005013-21 | Sponsor Protocol Number: EMR 62202-811 | Start Date*: 2009-01-23 | |||||||||||
| Sponsor Name:Institut de Cancérologie de la Loire | |||||||||||||
| Full Title: ERBITUX | |||||||||||||
| Medical condition: Locally advanced non small cell lung cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-005125-12 | Sponsor Protocol Number: LIRALUNG | Start Date*: 2016-05-12 |
| Sponsor Name:Dr. Albert Lecube, Ph.D., M.D. | ||
| Full Title: MULTICENTRE RANDOMIZED DOUBLE BLIND, CROSSOVER, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFECT OF LIRAGLUTIDE ON LUNG FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (LIRALUNG STUDY) | ||
| Medical condition: Type 2 Diabetes | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: (No results available) | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.